Mepolizumab for Hives
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does require that you have not used Xolair before. It's best to discuss your current medications with the trial team.
What data supports the effectiveness of the drug Mepolizumab for treating hives?
Is Mepolizumab safe for humans?
How does the drug mepolizumab differ from other treatments for hives?
Mepolizumab is unique because it is a monoclonal antibody that targets interleukin-5 (IL-5), a protein involved in the activation of eosinophils (a type of white blood cell), which are key in inflammation. While it is primarily used for severe eosinophilic asthma, its mechanism of reducing eosinophil activity may offer a novel approach for treating hives, especially if they are related to eosinophilic activity.610111213
What is the purpose of this trial?
This trial is testing Mepolizumab, a medication that reduces inflammation, in patients with chronic spontaneous urticaria who do not respond well to typical treatments. The drug works by decreasing the number of certain immune cells that cause hives and itching.
Research Team
Jason C Sluzevich, M.D.
Principal Investigator
Study Principal Investigator
Eligibility Criteria
This trial is for adults over 18 with chronic spontaneous urticaria (hives) that doesn't get better with antihistamines. Participants must be in good health overall and able to follow the study's procedures. Pregnant or nursing women, those planning pregnancy soon, people allergic to Nucala, severe asthma patients on high-dose steroids, and anyone who has used Xolair can't join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 200 mg SC of mepolizumab at weeks 0, 2, 4, 6, and 8, with assessments of UAS7, ISS, and UCT scores
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Mepolizumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
GlaxoSmithKline
Industry Sponsor
Dame Emma Walmsley
GlaxoSmithKline
Chief Executive Officer since 2017
MA in Classics and Modern Languages from Oxford University
Dr. Hal Barron
GlaxoSmithKline
Chief Medical Officer since 2018
MD from Harvard Medical School